158 related articles for article (PubMed ID: 26468947)
1. Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Cerbone L; Sternberg CN; Sengeløv L; Agerbaek M; Van Herpen C; Marreaud S; Collette S; Zhang J; Daugaard G
Oncology; 2016; 90(1):21-8. PubMed ID: 26468947
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE; Vukelja S; Atienza D; Awasthi S; Delaune R; Deutsch M; Dien PY; Gregory TF; Kolodziej MJ; Muscato JJ; Raju RN; Ruxer RL; Mull S; Ilegbodu D; Hood K; Nicol S; Berry W
Invest New Drugs; 2008 Apr; 26(2):151-8. PubMed ID: 18236006
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Narayan V; Mamtani R; Keefe S; Guzzo T; Malkowicz SB; Vaughn DJ
Cancer Res Treat; 2016 Jul; 48(3):1084-91. PubMed ID: 26639198
[TBL] [Abstract][Full Text] [Related]
4. A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Park IH; Lee KS; Kang HS; Kim SW; Lee S; Jung SY; Kwon Y; Shin KH; Ko K; Nam BH; Ro J
Invest New Drugs; 2012 Oct; 30(5):1972-7. PubMed ID: 22006161
[TBL] [Abstract][Full Text] [Related]
5. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
McHugh LA; Kriajevska M; Mellon JK; Griffiths TR
Urology; 2007 Feb; 69(2):390-4. PubMed ID: 17320695
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
van der Noll R; Smit WM; Wymenga AN; Boss DS; Grob M; Huitema AD; Rosing H; Tibben MM; Keessen M; Rehorst H; Beijnen JH; Schellens JH
Invest New Drugs; 2015 Dec; 33(6):1197-205. PubMed ID: 26362459
[TBL] [Abstract][Full Text] [Related]
8. Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.
Powles T; Huddart RA; Elliott T; Sarker SJ; Ackerman C; Jones R; Hussain S; Crabb S; Jagdev S; Chester J; Hilman S; Beresford M; Macdonald G; Santhanam S; Frew JA; Stockdale A; Hughes S; Berney D; Chowdhury S
J Clin Oncol; 2017 Jan; 35(1):48-55. PubMed ID: 28034079
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
Hussain SA; Stocken DD; Riley P; Palmer DH; Peake DR; Geh JI; Spooner D; James ND
Br J Cancer; 2004 Aug; 91(5):844-9. PubMed ID: 15292922
[TBL] [Abstract][Full Text] [Related]
10. An European Organisation for Research and Treatment of Cancer phase I study of lapatinib and docetaxel as neoadjuvant treatment for human epidermal growth factor receptor 2 (HER2) positive locally-advanced/inflammatory or large operable breast cancer.
Bonnefoi H; Zaman K; Debled M; Fiche M; Fournier M; Nobahar M; Pierga JY; Koch KM; Bartlett J; Zimmer A; Marreaud S; Bogaerts J; Cameron D
Eur J Cancer; 2013 Jan; 49(2):281-9. PubMed ID: 22999386
[TBL] [Abstract][Full Text] [Related]
11. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Brugnatelli S; Danova M; De Bella MT; Vaglica M; Manuguerra G; Riccardi A; Palmeri S
Oncology; 2002; 62(1):33-8. PubMed ID: 11810041
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Gunlusoy B; Arslan M; Vardar E; Degirmenci T; Kara C; Ceylan Y; Kozacıoğlu Z
Actas Urol Esp; 2012 Oct; 36(9):515-20. PubMed ID: 22819345
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Watanabe A; Kida M; Miyazawa S; Iwai T; Okuwaki K; Kaneko T; Yamauchi H; Takezawa M; Imaizumi H; Koizumi W
World J Gastroenterol; 2015 May; 21(19):5979-84. PubMed ID: 26019463
[TBL] [Abstract][Full Text] [Related]
14. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
[TBL] [Abstract][Full Text] [Related]
15. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Deeken JF; Wang H; Subramaniam D; He AR; Hwang J; Marshall JL; Urso CE; Wang Y; Ramos C; Steadman K; Pishvaian MJ
Cancer; 2015 May; 121(10):1645-53. PubMed ID: 25641763
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Kim RD; Alberts SR; Peña C; Genvresse I; Ajavon-Hartmann A; Xia C; Kelly A; Grilley-Olson JE
Br J Cancer; 2018 Feb; 118(4):462-470. PubMed ID: 29348486
[TBL] [Abstract][Full Text] [Related]
18. Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Galsky MD; Posner M; Holcombe RF; Lee KM; Misiukiewicz K; Tsao CK; Godbold J; Soto R; Gimpel-Tetra K; Lowe N; Oh WK
Cancer Chemother Pharmacol; 2014 Sep; 74(3):465-71. PubMed ID: 25023489
[TBL] [Abstract][Full Text] [Related]
19. [Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Song Y; Yang L; Zhou A; Chi Y; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):212-6. PubMed ID: 24785283
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.
Salman HS; Tanaka K; Sparano JA
Clin Breast Cancer; 2002 Jan; 2(4):299-303. PubMed ID: 11899362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
